ClinicalTrials.gg
CompletedNCT02896855PUFFINUpdated Dec 16, 2021Results posted

A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

A Phase 3 interventional study of Docetaxel and Pertuzumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-16.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
29th of 104
243 · median 100
Started
2016
with 5 others
Phase 3
23 of 104
2 open now
Registered
47th of 104
by date
Lead sponsor
20 of 104
Hoffmann-La Roche

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 29th largest by enrollment, is one of 6 that started in 2016, is one of 23 in phase 3, and was the 47th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial in China will evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel compared with placebo + trastuzumab + docetaxel in participants with previously untreated HER2-positive metastatic breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the breast with locally recurrent or disease that is suitable for chemotherapy
  • -positive metastatic breast cancer (MBC)
  • (LVEF) greater than or equal to (>=) 55 percent (%) at baseline (within 42 days of randomization)
  • Performance Status of 0 or 1
  • Women of and men should agree to use an effective form of and to continue its use for the duration of study treatment and for at least 7 months after the last dose of study treatment (trastuzumab and/or pertuzumab)

Exclusion criteria

Exclusion Criteria:

  • History of anti-cancer therapy for MBC (with the exception of one prior hormonal regimen for MBC)
  • History of approved or investigative tyrosine kinase/HER inhibitors for breast cancer in any treatment setting, except trastuzumab used in the or adjuvant setting
  • History of systemic breast cancer treatment in the neo-adjuvant or adjuvant setting with a disease-free interval from completion of the systemic treatment (excluding hormonal therapy) to diagnosis of less than (\<) 12 months
  • History of persistent Grade >= 2 hematologic toxicity resulting from previous adjuvant therapy
  • Grade >= 3 peripheral neuropathy at randomization
  • History of other within the last 5 years, except for carcinoma in situ of the cervix or non-melanoma skin carcinoma that has been previously treated with curative intent
  • Current clinical or radiographic evidence of central nervous system (CNS) metastases
  • History of exposure to cumulative doses of anthracyclines
  • Current uncontrolled hypertension or unstable angina
  • History of congestive heart failure (CHF) of any (NYHA) classification, or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction within 6 months of randomization
  • History of decrease to \< 50% during or after prior trastuzumab neo-adjuvant or adjuvant therapy
  • Current dyspnea at rest due to complications of advanced malignancy, or other diseases that require continuous oxygen therapy
  • Inadequate organ function within 28 days prior to randomization
  • Current severe, uncontrolled systemic disease
  • Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during the course of study treatment
  • Pregnant or lactating women
  • History of receiving any treatment within 28 days of randomization
  • Current known infection with (HIV), virus (HCV), or active virus (HBV)
  • Receipt of intravenous (IV) antibiotics for infection within 14 days of randomization
  • Current chronic daily treatment with (excluding inhaled steroids)
  • Known to any of the protocol-specified study treatments
  • Concurrent participation in an interventional or noninterventional study
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
243 participants (actual)

Study arms

  • Active comparator
    Arm A: Placebo + Trastuzumab + Docetaxel

    Placebo matched to pertuzumab, trastuzumab (8-milligrams per kilogram \[mg/kg\] loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-milligrams per square meter \[mg/m\^2\]) were administered by intravenous (IV) infusion every 3 weeks until disease progression or unacceptable toxicity.

    Drug: Docetaxel · Drug: Placebo · Drug: Trastuzumab

  • Experimental
    Arm B: Pertuzumab + Trastuzumab + Docetaxel

    Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles), trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-mg/m\^2) were administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.

    Drug: Docetaxel · Drug: Pertuzumab · Drug: Trastuzumab

Interventions

  • Docetaxel (75-mg/m\^2) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.

  • Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.

    Also known as: Perjeta

  • DrugPlacebo

    Placebo matched to pertuzumab was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.

  • Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival, as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    Progression-free survival (PFS) was defined as the time from randomization to first occurrence of progressive disease (PD), as determined by the investigator using RECIST v1.1, or death from any cause within 18 weeks after the last tumor assessment, whichever occurred first. As per RECIST v1.1, PD is defined as a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeters (mm), and the appearance of new lesions. The Kaplan-Meier approach was used to estimate median PFS for each treatment arm. Data for participants who did not have a PFS event were censored at the time of the last tumor assessment (if no tumor assessments performed after baseline, at randomization plus 1 day).

    Time frame: From date of randomization until date of PFS event (Median [range] time on study for Arm A vs. Arm B at Primary analysis: 57.14 [3.3-93.3] weeks vs. 59.64 [0.9-90.4] weeks; Final analysis: 145.29 [3.3-225.3] weeks vs. 174.79 [0.9-226.1] weeks)

  2. Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Progression-Free Survival at 1 to 3 Years, as Determined by the Investigator Using RECIST v1.1

    Progression-free survival (PFS) was defined as the time from randomization to first occurrence of progressive disease (PD), as determined by the investigator using RECIST v1.1, or death from any cause within 18 weeks after the last tumor assessment, whichever occurred first. As per RECIST v1.1, PD is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm, and the appearance of new lesions. The Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for PFS at 1, 2, and 3 years. Data for participants who did not have a PFS event were censored at the time of the last tumor assessment (if no tumor assessments performed after baseline visit, at randomization plus 1 day). At final analysis, the median \[range\] time on study for Arm A vs. Arm B was 145.29 \[3.3-225.3\] weeks vs. 174.79 \[0.9-226.1\] weeks.

    Time frame: At 1, 2, and 3 years

Secondary outcomes

  1. Overall Survival

    Overall survival (OS) was defined as the time from randomization to death from any cause. The Kaplan-Meier approach was used to estimate median OS for each treatment arm. Participants who were alive or lost to follow-up at the time of the analysis were censored at the date they were last known to be alive. Participants with no post-baseline information were censored at the time of randomization plus 1 day. The results reported here are from the final analysis. At the primary completion date, the median duration of OS had not been reached and OS data was not considered mature due to the few number of events reported.

    Time frame: From date of randomization until the date of death from any cause (Median [range] time on study for Arm A vs. Arm B at Final analysis: 145.29 [3.3-225.3] weeks vs. 174.79 [0.9-226.1] weeks)

  2. Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival at 1 to 3 Years

    Overall survival (OS) was defined as the time from randomization to death from any cause. The Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS (i.e., alive) at 1, 2, and 3 years. Participants who were alive or lost to follow-up at the time of the analysis were censored at the date they were last known to be alive. Participants with no post-baseline information were censored at the time of randomization plus 1 day. At final analysis, the median \[range\] time on study for Arm A vs. Arm B was 145.29 \[3.3-225.3\] weeks vs. 174.79 \[0.9-226.1\] weeks.

    Time frame: At 1, 2, and 3 Years

  3. Percentage of Participants With Measurable Disease at Baseline Who Achieved an Objective Response (Complete or Partial Response), as Determined by the Investigator Using RECIST v1.1

    An objective response was defined as a complete response (CR) or partial response (PR), as determined by the investigator using RECIST v1.1. As per RECIST v1.1, CR is defined as the disappearance of all target lesions, and PR is defined as at least a 30% decrease in the sum of diameters of target lesions. Also per RECIST v1.1, stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum on study; PD is defined as a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm, and the appearance of new lesions. The same assessment technique must be used throughout the study for evaluating a particular lesion, and the same investigator should assess all tumor responses for each participant. Participants without a post-baseline tumor assessment were considered non-responders.

    Time frame: At Baseline and every 9 weeks from date of randomization until disease progression or death, whichever occurs first (Median [range] time on study for Arm A vs. Arm B at Primary analysis: 57.14 [3.3-93.3] weeks vs. 59.64 [0.9-90.4] weeks)

  4. Duration of Objective Response, as Determined by the Investigator Using RECIST v1.1

    Duration of objective response was defined as the time from the first occurrence of a documented objective response (complete response \[CR\] or partial response \[PR\]) to the time of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause within 18 weeks after the last tumor assessment, whichever occurred first. As per RECIST v1.1, CR is defined as the disappearance of all target lesions, and PR is defined as at least a 30% decrease in the sum of diameters of target lesions. The Kaplan-Meier approach was used to estimate median duration of objective response. Data for participants who did not have an event were censored at the time of the last tumor assessment (if no tumor assessments were performed after baseline visit, at randomization plus 1 day).

    Time frame: From date of first occurrence of documented objective response to date of event (Median [range] time on study for Arm A vs. Arm B at Primary analysis: 57.14 [3.3-93.3] weeks vs. 59.64 [0.9-90.4] weeks)

  5. Number of Participants With at Least One Adverse Event

    The number of participants per treatment arm experiencing at least one adverse event, including all non-serious and serious adverse events, is reported here. Adverse events reported prior to first crossover treatment were included in the Placebo arm, and in the Crossover arm after that date, for participants in Arm A who crossed over from placebo to pertuzumab. At final analysis, the median \[range\] time on study treatment with placebo or pertuzumab per arm was: Arm A - Placebo: 52.3 \[3-207\] weeks; Arm B - Pertuzumab: 66.1 \[3-225\] weeks; Arm A - Crossover to Pertuzumab: 18.1 \[12-24\] weeks.

    Time frame: From first dose of study drug until 42 days after last dose of study drug (up to 4 years, 4 months)

  6. Number of Participants With at Least One Grade ≥3 Adverse Event

    Adverse event (AE) severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0); if the AE was not specifically listed, the following grades of severity were used: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening or disabling; and Grade 5 = death. Severe and serious are not synonymous. Severity refers to the intensity of an AE, whereas a serious AE must meet criteria set out in the protocol; both were independently assessed for each AE. AEs reported prior to first crossover treatment were included in the Placebo arm, and in the Crossover arm after that date, for participants in Arm A who crossed over from placebo to pertuzumab. At final analysis, the median \[range\] time on study treatment with placebo or pertuzumab per arm was: Arm A - Placebo: 52.3 \[3-207\] weeks; Arm B - Pertuzumab: 66.1 \[3-225\] weeks; Arm A - Crossover to Pertuzumab: 18.1 \[12-24\] weeks.

    Time frame: From first dose of study drug until 42 days after last dose of study drug (up to 4 years, 4 months)

  7. Number of Participants With at Least One Adverse Event Leading to Withdrawal From Any Treatment

    Adverse events reported prior to first crossover treatment were included in the Placebo arm, and in the Crossover arm after that date, for participants in Arm A who crossed over from placebo to pertuzumab. At final analysis, the median \[range\] time on study treatment with placebo or pertuzumab per arm was: Arm A - Placebo: 52.3 \[3-207\] weeks; Arm B - Pertuzumab: 66.1 \[3-225\] weeks; Arm A - Crossover to Pertuzumab: 18.1 \[12-24\] weeks.

    Time frame: From first dose of study drug until 42 days after last dose of study drug (up to 4 years, 4 months)

  8. Number of Participants With Symptomatic Left Ventricular Systolic Dysfunction (LVSD), as Determined Using Echocardiography (ECHO) or Multiple-Gated Acquisition (MUGA) Scan

    The number of participants with symptomatic left ventricular systolic dysfunction (LVSD) at any time during the study, as determined using echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan, were summarized by treatment arm. Symptomatic LVSD was evaluated according to NCI CTCAE v4.0 (for "heart failure") and the New York Heart Association (NYHA) classification. At final analysis, the median \[range\] time on study treatment with placebo or pertuzumab per arm was: Arm A - Placebo: 52.3 \[3-207\] weeks; Arm B - Pertuzumab: 66.1 \[3-225\] weeks; Arm A - Crossover to Pertuzumab: 18.1 \[12-24\] weeks.

    Time frame: From first dose of study drug until 42 days after last dose of study drug (up to 4 years, 4 months)

  9. Number of Participants With an Asymptomatic Decline in Left Ventricular Ejection Fraction (LVEF) Event, as Determined Using ECHO or MUGA Scan

    An asymptomatic decline in LVEF event is reported as an adverse event of "ejection fraction decreased" and is defined as either of the following: an absolute decrease in LVEF of ≥10 percentage points from baseline to an LVEF of \<50%; or an asymptomatic decrease in LVEF requiring treatment or leading to discontinuation of pertuzumab (or placebo) and trastuzumab. At final analysis, the median \[range\] time on study treatment with placebo or pertuzumab per arm was: Arm A - Placebo: 52.3 \[3-207\] weeks; Arm B - Pertuzumab: 66.1 \[3-225\] weeks; Arm A - Crossover to Pertuzumab: 18.1 \[12-24\] weeks.

    Time frame: From first dose of study drug until 42 days after last dose of study drug (up to 4 years, 4 months)

  10. Number of Participants by the LVEF Abnormality Status Categories Over Time, as Determined by the Change From Baseline in LVEF Using ECHO or MUGA Scans

    Left ventricular ejection fraction (LVEF) is the measurement of how much blood is being pumped out of the left ventricle of the heart with each contraction. LVEF was calculated using the modified Simpson method and must have been ≥55% at baseline as determined by the local facility before a participant could be enrolled in the study. The investigator decided which method of LVEF assessment (ECHO \[preferred\] or MUGA scan) would be used for each participant at baseline, and the same method was to be used throughout the study, to the extent possible. The LVEF abnormality status categories, as a change relative to LVEF at baseline, included: Increase or no change in LVEF; Decrease of \<10 LVEF points; Absolute LVEF value ≥50% and a decrease of ≥10 LVEF points; and Absolute LVEF value \<50% and a decrease of ≥10 LVEF points. The overall worst LVEF value was defined as the lowest post-baseline value up to the end of the study, including unscheduled assessments and the post-treatment period.

    Time frame: Baseline, Weeks 9, 18, 27, 36, 45, 54, 63, 72, 81, 90, 99, 108, 117, 126, 135, 144, 153, 162, 171, 180, 189, 198, 207, 216, and 225, Study Drug Discontinuation Visit (up to 4 years, 4 months), and Treatment-Free Follow-Up at 6 months, and 1 and 2 years

  11. Baseline LVEF and Change From Baseline to Maximum On-Treatment Decrease in LVEF at Any Point During the Study

    The baseline left ventricular ejection fraction (LVEF) and change from baseline to the maximum on-treatment decrease in LVEF at any point during the study are reported here. LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. LVEF was calculated using the modified Simpson method and must have been ≥55% at baseline as determined by the local facility before a participant could be enrolled in the study. The investigator decided which method of LVEF assessment (ECHO \[preferred\] or MUGA scan) would be used for each participant at baseline, and the same method should have been used throughout the study, to the extent possible. At final analysis, the median \[range\] time on study for Arm A vs. Arm B was 145.29 \[3.3-225.3\] weeks vs. 174.79 \[0.9-226.1\] weeks.

    Time frame: Baseline and every 9 weeks from date of randomization until treatment discontinuation (up to 4 years, 4 months)

07

Results

Posted Jul 10, 2019

Participant flow

Participant flow — Overall Study
MilestoneArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + Docetaxel
Started121122
Received any study treatment120122
Crossed over from placebo to receive pertuzumab120
Completed4969
Not completed7253
Withdrew: Death5040
Withdrew: Lost to follow-up159
Withdrew: Withdrawal by subject74

Outcome measures

PrimaryProgression-Free Survival, as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

Progression-free survival (PFS) was defined as the time from randomization to first occurrence of progressive disease (PD), as determined by the investigator using RECIST v1.1, or death from any cause within 18 weeks after the last tumor assessment, whichever occurred first. As per RECIST v1.1, PD is defined as a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeters (mm), and the appearance of new lesions. The Kaplan-Meier approach was used to estimate median PFS for each treatment arm. Data for participants who did not have a PFS event were censored at the time of the last tumor assessment (if no tumor assessments performed after baseline, at randomization plus 1 day).

Time frame:
From date of randomization until date of PFS event (Median [range] time on study for Arm A vs. Arm B at Primary analysis: 57.14 [3.3-93.3] weeks vs. 59.64 [0.9-90.4] weeks; Final analysis: 145.29 [3.3-225.3] weeks vs. 174.79 [0.9-226.1] weeks)
Reported as:
Median · months
Progression-Free Survival, as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
monthsArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + Docetaxel
Primary Analysis12.4 (10.4 to 12.7)14.5 (12.5 to 18.6)
Final Analysis12.5 (10.4 to 14.6)16.5 (12.7 to 20.2)
Statistical analysis
  • Arm A: Placebo + Trastuzumab + Docetaxel vs Arm B: Pertuzumab + Trastuzumab + Docetaxel · Log Rank · p = 0.0418 · Stratified hazard ratio: 0.69 · 95% CI 0.49 to 0.99This stratified Hazard Ratio (HR) is calculated as Arm B: Pertuzumab versus Arm A: Placebo. Cox proportional hazards model, stratified by disease type and hormone-receptor status, was used to estimate HR and its 95% CI.
  • Arm A: Placebo + Trastuzumab + Docetaxel vs Arm B: Pertuzumab + Trastuzumab + Docetaxel · Log Rank · p = 0.0556 · Unstratified hazard ratio: 0.71 · 95% CI 0.50 to 1.01This unstratified Hazard Ratio (HR) is calculated as Arm B: Pertuzumab versus Arm A: Placebo. Cox proportional hazards model was used to estimate HR and its 95% CI.
  • Arm A: Placebo + Trastuzumab + Docetaxel vs Arm B: Pertuzumab + Trastuzumab + Docetaxel · Log Rank · p = 0.0008 · Stratified hazard ratio: 0.60 · 95% CI 0.45 to 0.81This stratified Hazard Ratio (HR) is calculated as Arm B: Pertuzumab versus Arm A: Placebo. Cox proportional hazards model, stratified by disease type and hormone-receptor status, was used to estimate HR and its 95% CI.
  • Arm A: Placebo + Trastuzumab + Docetaxel vs Arm B: Pertuzumab + Trastuzumab + Docetaxel · Log Rank · p = 0.0019 · Unstratified hazard ratio: 0.63 · 95% CI 0.47 to 0.85This unstratified Hazard Ratio (HR) is calculated as Arm B: Pertuzumab versus Arm A: Placebo. Cox proportional hazards model was used to estimate HR and its 95% CI.
PrimaryKaplan-Meier Estimate of the Percentage of Participants Event-Free for Progression-Free Survival at 1 to 3 Years, as Determined by the Investigator Using RECIST v1.1

Progression-free survival (PFS) was defined as the time from randomization to first occurrence of progressive disease (PD), as determined by the investigator using RECIST v1.1, or death from any cause within 18 weeks after the last tumor assessment, whichever occurred first. As per RECIST v1.1, PD is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm, and the appearance of new lesions. The Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for PFS at 1, 2, and 3 years. Data for participants who did not have a PFS event were censored at the time of the last tumor assessment (if no tumor assessments performed after baseline visit, at randomization plus 1 day). At final analysis, the median \[range\] time on study for Arm A vs. Arm B was 145.29 \[3.3-225.3\] weeks vs. 174.79 \[0.9-226.1\] weeks.

Time frame:
At 1, 2, and 3 years
Reported as:
Number · estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Progression-Free Survival at 1 to 3 Years, as Determined by the Investigator Using RECIST v1.1
estimate of percentage of participantsArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + Docetaxel
1 Year52.90 (43.75 to 62.04)66.37 (57.86 to 74.87)
2 Years19.19 (11.85 to 26.53)37.85 (29.03 to 46.66)
3 Years12.73 (6.48 to 18.97)29.44 (21.04 to 37.84)
SecondaryOverall Survival

Overall survival (OS) was defined as the time from randomization to death from any cause. The Kaplan-Meier approach was used to estimate median OS for each treatment arm. Participants who were alive or lost to follow-up at the time of the analysis were censored at the date they were last known to be alive. Participants with no post-baseline information were censored at the time of randomization plus 1 day. The results reported here are from the final analysis. At the primary completion date, the median duration of OS had not been reached and OS data was not considered mature due to the few number of events reported.

Time frame:
From date of randomization until the date of death from any cause (Median [range] time on study for Arm A vs. Arm B at Final analysis: 145.29 [3.3-225.3] weeks vs. 174.79 [0.9-226.1] weeks)
Reported as:
Median · months
Overall Survival
monthsArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + Docetaxel
Overall SurvivalNA (22.1 to NA)NA (30.6 to NA)
Statistical analysis
  • Arm A: Placebo + Trastuzumab + Docetaxel vs Arm B: Pertuzumab + Trastuzumab + Docetaxel · Log Rank · p = 0.0658 · Stratified hazard ratio: 0.68 · 95% CI 0.45 to 1.03This stratified Hazard Ratio (HR) is calculated as Arm B: Pertuzumab versus Arm A: Placebo. Cox proportional hazards model, stratified by disease type and hormone-receptor status, was used to estimate HR and its 95% CI.
  • Arm A: Placebo + Trastuzumab + Docetaxel vs Arm B: Pertuzumab + Trastuzumab + Docetaxel · Log Rank · p = 0.0864 · Unstratified hazard ratio: 0.70 · 95% CI 0.46 to 1.06This unstratified Hazard Ratio (HR) is calculated as Arm B: Pertuzumab versus Arm A: Placebo. Cox proportional hazards model was used to estimate HR and its 95% CI.
SecondaryKaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival at 1 to 3 Years

Overall survival (OS) was defined as the time from randomization to death from any cause. The Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS (i.e., alive) at 1, 2, and 3 years. Participants who were alive or lost to follow-up at the time of the analysis were censored at the date they were last known to be alive. Participants with no post-baseline information were censored at the time of randomization plus 1 day. At final analysis, the median \[range\] time on study for Arm A vs. Arm B was 145.29 \[3.3-225.3\] weeks vs. 174.79 \[0.9-226.1\] weeks.

Time frame:
At 1, 2, and 3 Years
Reported as:
Number · estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival at 1 to 3 Years
estimate of percentage of participantsArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + Docetaxel
1 Year90.64 (85.37 to 95.91)93.44 (89.05 to 97.84)
2 Years73.85 (65.80 to 81.91)78.87 (71.50 to 86.24)
3 Years58.41 (49.12 to 67.69)70.79 (62.50 to 79.09)
SecondaryPercentage of Participants With Measurable Disease at Baseline Who Achieved an Objective Response (Complete or Partial Response), as Determined by the Investigator Using RECIST v1.1

An objective response was defined as a complete response (CR) or partial response (PR), as determined by the investigator using RECIST v1.1. As per RECIST v1.1, CR is defined as the disappearance of all target lesions, and PR is defined as at least a 30% decrease in the sum of diameters of target lesions. Also per RECIST v1.1, stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum on study; PD is defined as a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm, and the appearance of new lesions. The same assessment technique must be used throughout the study for evaluating a particular lesion, and the same investigator should assess all tumor responses for each participant. Participants without a post-baseline tumor assessment were considered non-responders.

Time frame:
At Baseline and every 9 weeks from date of randomization until disease progression or death, whichever occurs first (Median [range] time on study for Arm A vs. Arm B at Primary analysis: 57.14 [3.3-93.3] weeks vs. 59.64 [0.9-90.4] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Measurable Disease at Baseline Who Achieved an Objective Response (Complete or Partial Response), as Determined by the Investigator Using RECIST v1.1
percentage of participantsArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + Docetaxel
Objective Response (CR + PR)69.1 (58.88 to 78.07)79.0 (70.01 to 86.38)
Complete Response (CR)8.2 (3.63 to 15.61)5.7 (2.13 to 12.02)
Partial Response (PR)60.8 (50.39 to 70.58)73.3 (63.81 to 81.49)
Stable Disease (SD)20.6 (13.07 to 30.03)15.2 (8.97 to 23.56)
Progressive Disease (PD)4.1 (1.13 to 10.22)3.8 (1.05 to 9.47)
Missing or Unevaluable6.2 (NA to NA)1.9 (NA to NA)
Statistical analysis
  • Arm A: Placebo + Trastuzumab + Docetaxel vs Arm B: Pertuzumab + Trastuzumab + Docetaxel · Cochran-Mantel-Haenszel · p = 0.1126 · Difference in objective response: 9.98 · 95% CI -2.65 to 22.60The difference in objective response is calculated as Arm B: Pertuzumab minus Arm A: Placebo. 95% CI was calculated using Hauck-Anderson method.
  • Arm A: Placebo + Trastuzumab + Docetaxel vs Arm B: Pertuzumab + Trastuzumab + Docetaxel · Fisher Exact · p = 0.1108 · Difference in objective response: 9.98 · 95% CI -2.65 to 22.60The difference in objective response is calculated as Arm B: Pertuzumab minus Arm A: Placebo. 95% CI was calculated using Hauck-Anderson method.
SecondaryDuration of Objective Response, as Determined by the Investigator Using RECIST v1.1

Duration of objective response was defined as the time from the first occurrence of a documented objective response (complete response \[CR\] or partial response \[PR\]) to the time of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause within 18 weeks after the last tumor assessment, whichever occurred first. As per RECIST v1.1, CR is defined as the disappearance of all target lesions, and PR is defined as at least a 30% decrease in the sum of diameters of target lesions. The Kaplan-Meier approach was used to estimate median duration of objective response. Data for participants who did not have an event were censored at the time of the last tumor assessment (if no tumor assessments were performed after baseline visit, at randomization plus 1 day).

Time frame:
From date of first occurrence of documented objective response to date of event (Median [range] time on study for Arm A vs. Arm B at Primary analysis: 57.14 [3.3-93.3] weeks vs. 59.64 [0.9-90.4] weeks)
Reported as:
Median · months
Duration of Objective Response, as Determined by the Investigator Using RECIST v1.1
monthsArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + Docetaxel
Duration of Objective Response, as Determined by the Investigator Using RECIST v1.110.4 (8.3 to 15.4)12.4 (10.6 to 14.9)
Statistical analysis
  • Arm A: Placebo + Trastuzumab + Docetaxel vs Arm B: Pertuzumab + Trastuzumab + Docetaxel · Log Rank · p = 0.2867 · Cox proportional hazard: 0.78 · 95% CI 0.49 to 1.24This stratified Hazard Ratio (HR) is calculated as Arm B: Pertuzumab versus Arm A: Placebo. Cox proportional hazards model, stratified by disease type and hormone-receptor status, was used to estimate HR and its 95% CI.
SecondaryNumber of Participants With at Least One Adverse Event

The number of participants per treatment arm experiencing at least one adverse event, including all non-serious and serious adverse events, is reported here. Adverse events reported prior to first crossover treatment were included in the Placebo arm, and in the Crossover arm after that date, for participants in Arm A who crossed over from placebo to pertuzumab. At final analysis, the median \[range\] time on study treatment with placebo or pertuzumab per arm was: Arm A - Placebo: 52.3 \[3-207\] weeks; Arm B - Pertuzumab: 66.1 \[3-225\] weeks; Arm A - Crossover to Pertuzumab: 18.1 \[12-24\] weeks.

Time frame:
From first dose of study drug until 42 days after last dose of study drug (up to 4 years, 4 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event
ParticipantsArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelArm A: Crossover to Pertuzumab + Trastuzumab + Docetaxel
Number of Participants With at Least One Adverse Event1151215
SecondaryNumber of Participants With at Least One Grade ≥3 Adverse Event

Adverse event (AE) severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0); if the AE was not specifically listed, the following grades of severity were used: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening or disabling; and Grade 5 = death. Severe and serious are not synonymous. Severity refers to the intensity of an AE, whereas a serious AE must meet criteria set out in the protocol; both were independently assessed for each AE. AEs reported prior to first crossover treatment were included in the Placebo arm, and in the Crossover arm after that date, for participants in Arm A who crossed over from placebo to pertuzumab. At final analysis, the median \[range\] time on study treatment with placebo or pertuzumab per arm was: Arm A - Placebo: 52.3 \[3-207\] weeks; Arm B - Pertuzumab: 66.1 \[3-225\] weeks; Arm A - Crossover to Pertuzumab: 18.1 \[12-24\] weeks.

Time frame:
From first dose of study drug until 42 days after last dose of study drug (up to 4 years, 4 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Grade ≥3 Adverse Event
ParticipantsArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelArm A: Crossover to Pertuzumab + Trastuzumab + Docetaxel
Number of Participants With at Least One Grade ≥3 Adverse Event83901
SecondaryNumber of Participants With at Least One Adverse Event Leading to Withdrawal From Any Treatment

Adverse events reported prior to first crossover treatment were included in the Placebo arm, and in the Crossover arm after that date, for participants in Arm A who crossed over from placebo to pertuzumab. At final analysis, the median \[range\] time on study treatment with placebo or pertuzumab per arm was: Arm A - Placebo: 52.3 \[3-207\] weeks; Arm B - Pertuzumab: 66.1 \[3-225\] weeks; Arm A - Crossover to Pertuzumab: 18.1 \[12-24\] weeks.

Time frame:
From first dose of study drug until 42 days after last dose of study drug (up to 4 years, 4 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event Leading to Withdrawal From Any Treatment
ParticipantsArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelArm A: Crossover to Pertuzumab + Trastuzumab + Docetaxel
Number of Participants With at Least One Adverse Event Leading to Withdrawal From Any Treatment10150
SecondaryNumber of Participants With Symptomatic Left Ventricular Systolic Dysfunction (LVSD), as Determined Using Echocardiography (ECHO) or Multiple-Gated Acquisition (MUGA) Scan

The number of participants with symptomatic left ventricular systolic dysfunction (LVSD) at any time during the study, as determined using echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan, were summarized by treatment arm. Symptomatic LVSD was evaluated according to NCI CTCAE v4.0 (for "heart failure") and the New York Heart Association (NYHA) classification. At final analysis, the median \[range\] time on study treatment with placebo or pertuzumab per arm was: Arm A - Placebo: 52.3 \[3-207\] weeks; Arm B - Pertuzumab: 66.1 \[3-225\] weeks; Arm A - Crossover to Pertuzumab: 18.1 \[12-24\] weeks.

Time frame:
From first dose of study drug until 42 days after last dose of study drug (up to 4 years, 4 months)
Reported as:
Count of participants · Participants
Number of Participants With Symptomatic Left Ventricular Systolic Dysfunction (LVSD), as Determined Using Echocardiography (ECHO) or Multiple-Gated Acquisition (MUGA) Scan
ParticipantsArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelArm A: Crossover to Pertuzumab + Trastuzumab + Docetaxel
Number of Participants With Symptomatic Left Ventricular Systolic Dysfunction (LVSD), as Determined Using Echocardiography (ECHO) or Multiple-Gated Acquisition (MUGA) Scan000
SecondaryNumber of Participants With an Asymptomatic Decline in Left Ventricular Ejection Fraction (LVEF) Event, as Determined Using ECHO or MUGA Scan

An asymptomatic decline in LVEF event is reported as an adverse event of "ejection fraction decreased" and is defined as either of the following: an absolute decrease in LVEF of ≥10 percentage points from baseline to an LVEF of \<50%; or an asymptomatic decrease in LVEF requiring treatment or leading to discontinuation of pertuzumab (or placebo) and trastuzumab. At final analysis, the median \[range\] time on study treatment with placebo or pertuzumab per arm was: Arm A - Placebo: 52.3 \[3-207\] weeks; Arm B - Pertuzumab: 66.1 \[3-225\] weeks; Arm A - Crossover to Pertuzumab: 18.1 \[12-24\] weeks.

Time frame:
From first dose of study drug until 42 days after last dose of study drug (up to 4 years, 4 months)
Reported as:
Count of participants · Participants
Number of Participants With an Asymptomatic Decline in Left Ventricular Ejection Fraction (LVEF) Event, as Determined Using ECHO or MUGA Scan
ParticipantsArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelArm A: Crossover to Pertuzumab + Trastuzumab + Docetaxel
Number of Participants With an Asymptomatic Decline in Left Ventricular Ejection Fraction (LVEF) Event, as Determined Using ECHO or MUGA Scan020
SecondaryNumber of Participants by the LVEF Abnormality Status Categories Over Time, as Determined by the Change From Baseline in LVEF Using ECHO or MUGA Scans

Left ventricular ejection fraction (LVEF) is the measurement of how much blood is being pumped out of the left ventricle of the heart with each contraction. LVEF was calculated using the modified Simpson method and must have been ≥55% at baseline as determined by the local facility before a participant could be enrolled in the study. The investigator decided which method of LVEF assessment (ECHO \[preferred\] or MUGA scan) would be used for each participant at baseline, and the same method was to be used throughout the study, to the extent possible. The LVEF abnormality status categories, as a change relative to LVEF at baseline, included: Increase or no change in LVEF; Decrease of \<10 LVEF points; Absolute LVEF value ≥50% and a decrease of ≥10 LVEF points; and Absolute LVEF value \<50% and a decrease of ≥10 LVEF points. The overall worst LVEF value was defined as the lowest post-baseline value up to the end of the study, including unscheduled assessments and the post-treatment period.

Time frame:
Baseline, Weeks 9, 18, 27, 36, 45, 54, 63, 72, 81, 90, 99, 108, 117, 126, 135, 144, 153, 162, 171, 180, 189, 198, 207, 216, and 225, Study Drug Discontinuation Visit (up to 4 years, 4 months), and Treatment-Free Follow-Up at 6 months, and 1 and 2 years
Reported as:
Count of participants · Participants
Number of Participants by the LVEF Abnormality Status Categories Over Time, as Determined by the Change From Baseline in LVEF Using ECHO or MUGA Scans
ParticipantsArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + Docetaxel
Week 9 — Increase or No Change in LVEF5763
Week 9 — Decrease <10 LVEF Points5152
Week 9 — Absolute Value ≥50% & Decrease ≥10 LVEF Points34
Week 9 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 18 — Increase or No Change in LVEF6162
Week 18 — Decrease <10 LVEF Points3345
Week 18 — Absolute Value ≥50% & Decrease ≥10 LVEF Points43
Week 18 — Absolute Value <50% & Decrease ≥10 LVEF Points01
Week 27 — Increase or No Change in LVEF5451
Week 27 — Decrease <10 LVEF Points3543
Week 27 — Absolute Value ≥50% & Decrease ≥10 LVEF Points35
Week 27 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 36 — Increase or No Change in LVEF4546
Week 36 — Decrease <10 LVEF Points2843
Week 36 — Absolute Value ≥50% & Decrease ≥10 LVEF Points34
Week 36 — Absolute Value <50% & Decrease ≥10 LVEF Points01
Week 45 — Increase or No Change in LVEF3436
Week 45 — Decrease <10 LVEF Points2943
Week 45 — Absolute Value ≥50% & Decrease ≥10 LVEF Points53
Week 45 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 54 — Increase or No Change in LVEF2638
Week 54 — Decrease <10 LVEF Points2734
Week 54 — Absolute Value ≥50% & Decrease ≥10 LVEF Points43
Week 54 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 63 — Increase or No Change in LVEF2130
Week 63 — Decrease <10 LVEF Points1733
Week 63 — Absolute Value ≥50% & Decrease ≥10 LVEF Points63
Week 63 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 72 — Increase or No Change in LVEF1726
Week 72 — Decrease <10 LVEF Points1531
Week 72 — Absolute Value ≥50% & Decrease ≥10 LVEF Points54
Week 72 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 81 — Increase or No Change in LVEF1929
Week 81 — Decrease <10 LVEF Points1224
Week 81 — Absolute Value ≥50% & Decrease ≥10 LVEF Points32
Week 81 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 90 — Increase or No Change in LVEF1724
Week 90 — Decrease <10 LVEF Points1120
Week 90 — Absolute Value ≥50% & Decrease ≥10 LVEF Points23
Week 90 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 99 — Increase or No Change in LVEF1421
Week 99 — Decrease <10 LVEF Points1023
Week 99 — Absolute Value ≥50% & Decrease ≥10 LVEF Points22
Week 99 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 108 — Increase or No Change in LVEF1315
Week 108 — Decrease <10 LVEF Points724
Week 108 — Absolute Value ≥50% & Decrease ≥10 LVEF Points13
Week 108 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 117 — Increase or No Change in LVEF1418
Week 117 — Decrease <10 LVEF Points318
Week 117 — Absolute Value ≥50% & Decrease ≥10 LVEF Points13
Week 117 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 126 — Increase or No Change in LVEF720
Week 126 — Decrease <10 LVEF Points915
Week 126 — Absolute Value ≥50% & Decrease ≥10 LVEF Points12
Week 126 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 135 — Increase or No Change in LVEF615
Week 135 — Decrease <10 LVEF Points818
Week 135 — Absolute Value ≥50% & Decrease ≥10 LVEF Points12
Week 135 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 144 — Increase or No Change in LVEF1018
Week 144 — Decrease <10 LVEF Points310
Week 144 — Absolute Value ≥50% & Decrease ≥10 LVEF Points13
Week 144 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 153 — Increase or No Change in LVEF712
Week 153 — Decrease <10 LVEF Points715
Week 153 — Absolute Value ≥50% & Decrease ≥10 LVEF Points03
Week 153 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 162 — Increase or No Change in LVEF717
Week 162 — Decrease <10 LVEF Points612
Week 162 — Absolute Value ≥50% & Decrease ≥10 LVEF Points01
Week 162 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 171 — Increase or No Change in LVEF710
Week 171 — Decrease <10 LVEF Points416
Week 171 — Absolute Value ≥50% & Decrease ≥10 LVEF Points12
Week 171 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 180 — Increase or No Change in LVEF98
Week 180 — Decrease <10 LVEF Points314
Week 180 — Absolute Value ≥50% & Decrease ≥10 LVEF Points01
Week 180 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 189 — Increase or No Change in LVEF56
Week 189 — Decrease <10 LVEF Points39
Week 189 — Absolute Value ≥50% & Decrease ≥10 LVEF Points10
Week 189 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 198 — Increase or No Change in LVEF46
Week 198 — Decrease <10 LVEF Points25
Week 198 — Absolute Value ≥50% & Decrease ≥10 LVEF Points10
Week 198 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 207 — Increase or No Change in LVEF25
Week 207 — Decrease <10 LVEF Points13
Week 207 — Absolute Value ≥50% & Decrease ≥10 LVEF Points00
Week 207 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 216 — Increase or No Change in LVEF13
Week 216 — Decrease <10 LVEF Points01
Week 216 — Absolute Value ≥50% & Decrease ≥10 LVEF Points00
Week 216 — Absolute Value <50% & Decrease ≥10 LVEF Points00
Week 225 — Increase or No Change in LVEF—1
Week 225 — Decrease <10 LVEF Points—0
Week 225 — Absolute Value ≥50% & Decrease ≥10 LVEF Points—0
Week 225 — Absolute Value <50% & Decrease ≥10 LVEF Points—0
Study Drug Discontinuation Visit — Increase or No Change in LVEF4545
Study Drug Discontinuation Visit — Decrease <10 LVEF Points2839
Study Drug Discontinuation Visit — Absolute Value ≥50% & Decrease ≥10 LVEF Points83
Study Drug Discontinuation Visit — Absolute Value <50% & Decrease ≥10 LVEF Points00
Treatment-Free Follow-Up at 6 Months — Increase or No Change in LVEF2018
Treatment-Free Follow-Up at 6 Months — Decrease <10 LVEF Points2018
Treatment-Free Follow-Up at 6 Months — Absolute Value ≥50% & Decrease ≥10 LVEF Points30
Treatment-Free Follow-Up at 6 Months — Absolute Value <50% & Decrease ≥10 LVEF Points00
Treatment-Free Follow-Up at 1 Year — Increase or No Change in LVEF134
Treatment-Free Follow-Up at 1 Year — Decrease <10 LVEF Points1014
Treatment-Free Follow-Up at 1 Year — Absolute Value ≥50% & Decrease ≥10 LVEF Points01
Treatment-Free Follow-Up at 1 Year — Absolute Value <50% & Decrease ≥10 LVEF Points00
Treatment-Free Follow-Up at 2 Years — Increase or No Change in LVEF12
Treatment-Free Follow-Up at 2 Years — Decrease <10 LVEF Points01
Treatment-Free Follow-Up at 2 Years — Absolute Value ≥50% & Decrease ≥10 LVEF Points21
Treatment-Free Follow-Up at 2 Years — Absolute Value <50% & Decrease ≥10 LVEF Points00
Overall Worst LVEF Value (Maximum LVEF Decrease) — Increase or No Change in LVEF2120
Overall Worst LVEF Value (Maximum LVEF Decrease) — Decrease <10 LVEF Points7575
Overall Worst LVEF Value (Maximum LVEF Decrease) — Absolute Value ≥50% & Decrease ≥10 LVEF Points1622
Overall Worst LVEF Value (Maximum LVEF Decrease) — Absolute Value <50% & Decrease ≥10 LVEF Points02
SecondaryBaseline LVEF and Change From Baseline to Maximum On-Treatment Decrease in LVEF at Any Point During the Study

The baseline left ventricular ejection fraction (LVEF) and change from baseline to the maximum on-treatment decrease in LVEF at any point during the study are reported here. LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. LVEF was calculated using the modified Simpson method and must have been ≥55% at baseline as determined by the local facility before a participant could be enrolled in the study. The investigator decided which method of LVEF assessment (ECHO \[preferred\] or MUGA scan) would be used for each participant at baseline, and the same method should have been used throughout the study, to the extent possible. At final analysis, the median \[range\] time on study for Arm A vs. Arm B was 145.29 \[3.3-225.3\] weeks vs. 174.79 \[0.9-226.1\] weeks.

Time frame:
Baseline and every 9 weeks from date of randomization until treatment discontinuation (up to 4 years, 4 months)
Reported as:
Mean · percentage points of LVEF
Baseline LVEF and Change From Baseline to Maximum On-Treatment Decrease in LVEF at Any Point During the Study
percentage points of LVEFArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + Docetaxel
Baseline LVEF (value at visit)64.23 ± 4.9065.08 ± 4.43
Change from Baseline to Max Decrease in LVEF-4.88 ± 5.41-5.48 ± 5.06
Statistical analysis
  • Arm A: Placebo + Trastuzumab + Docetaxel vs Arm B: Pertuzumab + Trastuzumab + Docetaxel · Mean difference (net): -0.60 · 95% CI -1.96 to 0.75The treatment difference for change from baseline to maximum on-treatment decrease in LVEF is defined as Arm B: Pertuzumab minus Arm A: Placebo.

Adverse events

Collected over From first dose of study drug until 42 days after last dose of study drug (up to 4 years, 4 months). At final analysis, the median [range] time on study treatment with placebo or pertuzumab per arm was: Arm A - Placebo: 52.3 [3-207] weeks; Arm B - Pertuzumab: 66.1 [3-225] weeks; Arm A - Crossover to Pertuzumab: 18.1 [12-24] weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Placebo + Trastuzumab + Docetaxel50/120 (41.7%)23/120 (19.2%)114/120 (95%)
Arm B: Pertuzumab + Trastuzumab + Docetaxel40/122 (32.8%)30/122 (24.6%)119/122 (97.5%)
Arm A: Crossover to Pertuzumab + Trastuzumab + Docetaxel0/12 (0%)1/12 (8.3%)5/12 (41.7%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelArm A: Crossover to Pertuzumab + Trastuzumab + Docetaxel
Large intestine polypGastrointestinal disorders0/1200/1221/12
Peripheral arterial occlusive diseaseVascular disorders0/1200/1221/12
NeutropeniaBlood and lymphatic system disorders8/1209/1220/12
PneumoniaInfections and infestations3/1205/1220/12
Febrile neutropeniaBlood and lymphatic system disorders4/1203/1220/12
LeukopeniaBlood and lymphatic system disorders2/1203/1220/12
Alanine aminotransferase increasedInvestigations2/1200/1220/12
Cardiac tamponadeCardiac disorders0/1202/1220/12
Ventricular arrhythmiaCardiac disorders1/1200/1220/12
DeathGeneral disorders1/1201/1220/12
Most frequent other events
Showing 10 of 56
Most frequent other events
EventArm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelArm A: Crossover to Pertuzumab + Trastuzumab + Docetaxel
LeukopeniaBlood and lymphatic system disorders87/12091/1220/12
NeutropeniaBlood and lymphatic system disorders81/12087/1221/12
AnaemiaBlood and lymphatic system disorders58/12067/1220/12
Alanine aminotransferase increasedInvestigations56/12045/1221/12
DiarrhoeaGastrointestinal disorders28/12056/1220/12
AlopeciaSkin and subcutaneous tissue disorders40/12050/1220/12
Aspartate aminotransferase increasedInvestigations49/12045/1222/12
PyrexiaGeneral disorders21/12029/1220/12
CoughRespiratory, thoracic and mediastinal disorders17/12026/1220/12
AstheniaGeneral disorders20/12025/1220/12

Baseline characteristics

Intent-to-Treat (ITT) population: consists of all randomized participants, regardless of whether they received any study treatment. Participants are grouped according to the treatment group to which they were randomized.

Age, Continuous
Age, Continuous(years)Arm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelTotal
Mean51.3 ± 11.250.7 ± 10.651.0 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelTotal
Female121122243
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelTotal
Asian121122243
Disease Type: Visceral or Non-Visceral Disease
Disease Type: Visceral or Non-Visceral Disease(Participants)Arm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelTotal
Visceral Disease8688174
Non-Visceral Disease353469
Hormone Receptor Status
Hormone Receptor Status(Participants)Arm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelTotal
Estrogen and Progesterone Receptor Negative4853101
Estrogen and/or Progesterone Receptor Positive7369142
Measurable or Non-Measurable Disease, According to RECIST v1.1
Measurable or Non-Measurable Disease, According to RECIST v1.1(Participants)Arm A: Placebo + Trastuzumab + DocetaxelArm B: Pertuzumab + Trastuzumab + DocetaxelTotal
Measurable Disease97105202
Non-Measurable Disease241741
08

Study locations

15 sites
  • CHINESE ACADEMY OF MEDICAL SCIENCE; CANCER INST. & HOSPITAL; Medical ward
    Beijing, 100021, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Chinese PLA General Hospital
    Beijing, 100853, China
  • the First Hospital of Jilin University
    Changchun, 130021, China
  • Changzhou First People's Hospital
    Changzhou, 213003, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • The 900th Hospital of PLA joint service support force
    Fuzhou, 110016, China
  • Guangdong General Hospital
    Guangzhou, 510080, China
  • Harbin Medical University Cancer Hospital
    Harbin, 150081, China
  • Jiangsu Cancer Hospital
    Nanjing City, 211100, China
  • Jiangsu province hospital; surgery on galactophore
    Nanjing, 210029, China
  • Fudan University Shanghai Cancer Center
    Shanghai City, 200120, China
  • First Hospital of China Medical University
    Shenyang, 110001, China
  • Liaoning cancer Hospital & Institute
    Shenyang, 110042, China
  • Zhejiang Cancer Hospital
    Zhejiang, 310022, China
09

References and documents

Publications

  • Xu B, Li W, Zhang Q, Shao Z, Li Q, Wang X, Li H, Sun T, Yin Y, Zheng H, Feng J, Zhang H, Lei G, Restuccia E. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat. 2020 Aug;182(3):689-697. doi: 10.1007/s10549-020-05728-w. Epub 2020 Jun 20. PubMed 32564260 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Jun 2018, 21 months.

Results were first posted in Jul 2019, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 21 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2016
First posted
Sep 12, 2016
StartActual
Sep 13, 2016
Primary completionActual
Jun 27, 2018
CompletionActual
Jan 22, 2021
Results first posted
Jul 10, 2019
Last update
Dec 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02896855
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 12, 2016
Start date
Sep 13, 2016
Primary completion
Jun 27, 2018
Completion
Jan 22, 2021
Results posted
Jul 10, 2019
Last update
Dec 16, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion